Cargando…
Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design
BACKGROUND: The impact of COVID-19-related healthcare changes on access to buprenorphine (BUP) nationwide in the US is unknown. METHODS: We conducted an interrupted time series with the IQVIA LRx database. The study timeline included BUP prescriptions from 52 weeks before (2/23/19–2/21/20) to 52 wee...
Autores principales: | Roy, Payel Jhoom, Callaway Kim, Katherine, Suda, Katie, Luo, Jing, Wang, Xiaoming, Olejniczak, Donna, Liebschutz, Jane M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851915/ https://www.ncbi.nlm.nih.gov/pubmed/36694665 http://dx.doi.org/10.1016/j.dadr.2023.100135 |
Ejemplares similares
-
Emergency-department initiated buprenorphine: Impact on quality of life
por: Carroll, Caleb, et al.
Publicado: (2023) -
The introduction of a novel formulation of buprenorphine into organized health systems()()
por: Mullen, William, et al.
Publicado: (2022) -
Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022) -
Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program
por: Ward, Kathleen M., et al.
Publicado: (2022) -
Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
por: Winstanley, Erin L., et al.
Publicado: (2022)